Remepy Raises $36 Million Series A To Advance Hybridopa Phase III And Hybrid Drug Pipeline
By Amit Chowdhry ● Aug 12, 2026
Remepy has raised $36 million in Series A funding to expand its Hybrid Drug pipeline, accelerate pharmaceutical partnerships, and fund global Phase III development of Hybridopa for Parkinson’s disease. The financing brings the company’s total capital raised to $62 million. O.G. Venture Partners and M Ventures, the strategic venture arm of Merck KGaA, Darmstadt, Germany, led the round. Investors also included NFX, Vine Ventures, Qumra Capital, TechAviv, 97212 Ventures, Fresh Fund, PsyMed Ventures, Tadmor Group, Key1 Capital, and IT-Farm.